RIDDLE&CODE
25.5.2021 10:32:07 CEST | Business Wire | Press release
RIDDLE&CODE FinTech Solutions, an innovative European company empowering financial institutions to handle all aspects of digital asset management, has obtained a licence as a "service provider for virtual/cryptographic tokens'' by the Austrian Financial Market Authority (FMA). RIDDLE&CODE FinTech Solutions is one of the first fintech companies in Austria to be registered with FMA.
The company is devoted to promoting tokenization of industrial services, where regulatory requirements are still in development and challenging to meet. Following successful registration, RIDDLE&CODE and its Token Management Platform—which have already been fully audited and accepted by Switzerland's regulator FINMA—are now licenced to safeguard and issue payment and utility tokens.
"With the FMA registration, RIDDLE&CODE is one step closer to becoming the leading—and at the same time fully compliant—tokenization provider in the industrial sector. We have been a trusted partner of the industry for two years and are pleased to extend our activities to enable new business models and services through tokenization," said Alexander Koppel, CEO of RIDDLE&CODE.
"The official FMA approval is a strategic milestone for RIDDLE&CODE. We are pleased that we could make an important contribution to the company's success, demonstrating, once again, our expertise in the fintech industry," concluded Raphael Toman, Associated Partner at BRANDL TALOS.
RIDDLE&CODE FinTech Solutions
RIDDLE&CODE FinTech Solutions, a subsidiary firm of the leading European blockchain interface company RIDDLE&CODE, builds hardware and software stacks that empower funds, crypto exchanges and regulated financial institutions to manage all aspects of key generation, custody, AML, regulatory compliance and token management with unmatched versatility and security.
BRANDL TALOS
BRANDL TALOS is one of the leading Austrian law firms in the area of banking and finance and advices all players in the financial services arena – from established banks, new fintech firms, and companies raising capital alike. For more than 20 years, we have been leading Austrian and international corporations to success on the financial markets, not matter whether we deal with classical payment methods, cryptocurrencies, EU-regulations or international sanction mechanisms. We assist with license applications, advise you on dealing with regulators, help you find your way through the regulatory framework, and handle cases before the administrative courts and the civil courts – all this while also publishing the leading commentary on the Securities Supervision Act and the Capital Markets Act. Leave the law to us so that you can concentrate on running your business!
View source version on businesswire.com: https://www.businesswire.com/news/home/20210525005398/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom